Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study
Pembrolizumab plus lenvatinib with reduced-dose GEMOX demonstrated promising efficacy and a favorable safety profile in advanced BTC, suggesting that chemotherapy de-escalation may optimize the efficacy-toxicity balance. Further randomized studies are warranted to confirm these findings and refine biomarker-based treatment selections.
Authors
- Hongyun Zhao (ORCID: https://orcid.org/0000-0002-1251-3888)
- Chang Li (ORCID: https://orcid.org/0000-0002-3267-1859)
- M. Piao
- Guang Tan (ORCID: https://orcid.org/0009-0004-5583-187X)
- Z. Zhu
- Jiongyuan Li
- Rong Liu
- Nan Zhang
- Shuofeng Li
- Chao Liu
- Xiaobo Yang
- Xiangde Shi
- Fei Wang
- Xu Luo
Institutions
- Sun Yat-sen University (CN)
- Dalian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Chinese PLA General Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-014653
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking Union Medical College Hospital